Moderna announces new england journal of medicine publication of pivotal phase 3 clinical safety and efficacy data for mrna-1345, the company's investigational respiratory syncytial virus (rsv) vaccine

Moderna has submitted marketing authorizations globally for mrna-1345 and continues to prepare for an expected 2024 marketing launch cambridge, ma / accesswire / december 15, 2023 / moderna, inc. (nasdaq:mrna) today announced the publication of positive phase 3 clinical study results evaluating mrna-1345, its vaccine candidate for respiratory syncytial virus (rsv), in the new england journal of medicine . the peer-reviewed article summarizes safety and efficacy data from conquerrsv, the company's phase 2-3 trial evaluating mrna-1345.
MRNA Ratings Summary
MRNA Quant Ranking